Financhill
Back

Mesoblast Quote, Financials, Valuation and Earnings

Mesoblast Price Quote

$14.59
-0.01 (-12.95%)
(Updated: December 21, 2024 at 5:36 AM ET)

Mesoblast Key Stats

Sell
46
Mesoblast (MESO) is a Sell

Day range:
$13.70 - $15.67
52-week range:
$1.61 - $19.15
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
151.34
P/B ratio:
3.47%

Volume:
1.9M
Avg. volume:
469.1K
1-year change:
595%
Market cap:
$1.7B
Revenue:
$5.9M
EPS:
$0

How Much Does Mesoblast Make?

Data Unavailable

Is Mesoblast Growing As A Company?

Data Unavailable

Mesoblast Stock Price Performance

  • Did Mesoblast Stock Go Up Last Month?
    Mesoblast share price went up by 41.29% last month
  • Did MESO's Share Price Rise Over The Last Year?
    MESO share price rose by 595% over the past 1 year

What Is Mesoblast 52-Week High & Low?

  • What Is Mesoblast’s 52-Week High Share Price?
    Mesoblast has traded as high as $19.15 over the past 52 weeks
  • What Is Mesoblast’s 52-Week Low Share Price?
    Mesoblast has traded as low as $1.61 over the past 52 weeks

Mesoblast Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Mesoblast?

Data Unavailable

Is Mesoblast Cash Flow Positive?

Data Unavailable

Mesoblast Return On Invested Capital

Data Unavailable

Mesoblast Earnings Date & Stock Price

  • What Is Mesoblast's Stock Price Today?
    A single share of MESO can be purchased today for 14.60
  • What Is Mesoblast’s Stock Symbol?
    Mesoblast trades on the nasdaq under the ticker symbol: MESO
  • When Is Mesoblast’s Next Earnings Date?
    The next quarterly earnings date for Mesoblast is scheduled on January 31, 2025
  • When Is MESO's next ex-dividend date?
    Mesoblast's next ex-dividend date is December 22, 2024
  • How To Buy Mesoblast Stock?
    You can buy Mesoblast shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Mesoblast Competitors

  • Who Are Mesoblast's Competitors?
    Below is a list of companies who compete with Mesoblast or are related in some way:
    • Alterity Therapeutics Ltd (ATHE)
    • Immutep Ltd (IMMP)
    • Immuron Ltd (IMRN)
    • Kazia Therapeutics Ltd (KZIA)
    • Opthea Ltd (OPT)

Mesoblast Dividend Yield

Data Unavailable

Mesoblast Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 22.50
Upside from Last Price: 54.16%

Major Shareholders

Data Unavailable